ReviewCureus2024
Impact of Antenatal Corticosteroids on Cortisol and Glucose Homeostasis Levels in Preterm Neonates: A Meta-Analysis.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antenatal corticosteroids (ACS) are widely used to reduce respiratory distress syndrome (RDS) in preterm neonates, enhancing neonatal outcomes. However, the potential effects of ACS on other aspects of neonatal health, such as cortisol levels and glucose regulation, remain a concern. This study examines whether ACS administration impacts cortisol and glucose homeostasis in preterm infants by analyzing data from 14 selected studies. Using a random-effects model, we found no significant impact of ACS on cortisol levels (mean differences (MD) 2.23, confidence interval (CI) 5.26 to -0.80) or blood glucose levels (standard mean differences (SMD) 0.18, CI 0.00 to 0.35). Additionally, there was no notable difference in hypoglycemia risk between groups receiving ACS and those unexposed (odds ratio (OR) 1.46, CI 0.99 to 2.17). Subgroup and sensitivity analyses reinforced these findings, underscoring their robustness, and risk-of-bias assessment confirmed a low risk across the included studies. Our findings support the safety of ACS for cortisol and glucose levels in preterm infants, affirming its continued use for lung development while recommending vigilant blood glucose monitoring to manage potential hypoglycemia. These results provide essential insights for neonatal care protocols, contributing to the overall welfare of premature infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.